{"trials":[{"id":5930,"nct_id":"NCT07818564","title":"Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation","sponsor":"Brown University","registry_url":"https://clinicaltrials.gov/study/NCT07818564","tracker_url":"publication.php?id=5930","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-10","last_update_date":"2026-10-08","start_date":"2026-11","primary_completion_date":"2027-11","completion_date":"2027-11","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Phase I"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Inactive Placebo (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"989968603bde40ea62cec15821beab8b75357cd99d372a1c9c6f3bbeebc55d37","facility":"Brown University School of Public Health","city":"Providence","region":"Rhode Island","country":"United States","lat":41.823990000000002,"lon":-71.41283}],"countries":["United States"]},{"id":5746,"nct_id":"NCT07721467","title":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease","sponsor":"National Institute on Aging (NIA)","registry_url":"https://clinicaltrials.gov/study/NCT07721467","tracker_url":"publication.php?id=5746","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-10-06","last_update_date":"2026-10-08","start_date":"2026-10-13","primary_completion_date":"2030-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Alzheimer's Disease"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Cognitive Training","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"28a3d9c38002b595ae213eb3bb81b2024aaf1d5bdcc3b9fd3ac81fe627252323","facility":"National Institute of Aging, Clinical Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3490,"nct_id":"NCT07570654","title":"A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sponsor":"COMPASS Pathways","registry_url":"https://clinicaltrials.gov/study/NCT07570654","tracker_url":"publication.php?id=3490","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-10-06","start_date":"2026-09","primary_completion_date":"2028-11","completion_date":"2029-09","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":300,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"interventions":[{"name":"COMP360 psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934}],"countries":["United States","Canada"]},{"id":3686,"nct_id":"NCT07610135","title":"PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07610135","tracker_url":"publication.php?id=3686","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-10-30","primary_completion_date":"2028-06","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Mood (Psychological Function)","Well Being","Mood","Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Inactive Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3660,"nct_id":"NCT07332143","title":"The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD","sponsor":"Emory University","registry_url":"https://clinicaltrials.gov/study/NCT07332143","tracker_url":"publication.php?id=3660","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-10-01","start_date":"2026-06-08","primary_completion_date":"2027-03","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":150,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"psilocybin","type":"DRUG"},{"name":"Supportive Therapy","type":"BEHAVIORAL"},{"name":"Prolonged Exposure Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999}],"countries":["United States"]},{"id":5845,"nct_id":"NCT07610369","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07610369","tracker_url":"publication.php?id=5845","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-28","start_date":"2026-07-10","primary_completion_date":"2030-07","completion_date":"2030-07","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression","Parkinson's Disease (PD)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3455,"nct_id":"NCT06988319","title":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","sponsor":"Oregon Health and Science University","registry_url":"https://clinicaltrials.gov/study/NCT06988319","tracker_url":"publication.php?id=3455","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-23","start_date":"2026-11-01","primary_completion_date":"2027-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Chronic Pelvic Pain"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c0770de3d29c4c5f32a2af8475f2c25f664dc150eb0612e3bad6f32b5afb5313","facility":"Oregon Health & Science University","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621}],"countries":["United States"]},{"id":3575,"nct_id":"NCT07210112","title":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","sponsor":"Centre Hospitalier St Anne","registry_url":"https://clinicaltrials.gov/study/NCT07210112","tracker_url":"publication.php?id=3575","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-09-21","start_date":"2026-06-30","primary_completion_date":"2029-12-31","completion_date":"2030-06-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":112,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression - Major Depressive Disorder","Treatment-resistant Depression (TRD)"],"interventions":[{"name":"Psilocybin 25 mg per os","type":"DRUG"},{"name":"Trazodone 5mg","type":"DRUG"},{"name":"Trazodone 30 mg","type":"DRUG"},{"name":"Placebo of psilocybin","type":"DRUG"},{"name":"Placebo of trazodone","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"20f0c712ea58b6615610fe11e7cff939bcc55adfffcd8761309ca251e8acfc7d","facility":"GHU Paris Psychiatrie and Neurosciences","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002}],"countries":["France"]},{"id":3495,"nct_id":"NCT07516405","title":"A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sponsor":"University of Colorado, Denver","registry_url":"https://clinicaltrials.gov/study/NCT07516405","tracker_url":"publication.php?id=3495","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-16","start_date":"2026-04-01","primary_completion_date":"2028-03","completion_date":"2028-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy Volunteer","Older Adults (65-85 Years)"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d57f1d479805418491a2b4e825f4a61463da217d6483cb15a9c517f345d284","facility":"University of California San Francisco (UCSF) Department of Neurology","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"0473ab642c74b3812c946daf78fe3c51c20132227d55cd3b18f186955bf391f2","facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"2392816208ad8a6692839d858f70a09054f7ea063608cc805707f539d666e13b","facility":"Emory University Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"22268aacd3575a268c889e749c8576127c9bff8a9e8343b4058a94d77d976383","facility":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"bf586d38e3cc5e261d1c6e575c24ec47a2175ffd3a3a156c666afe314b54f80c","facility":"New York University Langone Health, Center for Psychedelic Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3709,"nct_id":"NCT07180108","title":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07180108","tracker_url":"publication.php?id=3709","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2025-08-12","primary_completion_date":"2028-06","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Psilocybin","Music Intervention"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Playlist 1","type":"BEHAVIORAL"},{"name":"Playlist 2","type":"BEHAVIORAL"},{"name":"Playlist 3","type":"BEHAVIORAL"},{"name":"Playlist 4","type":"BEHAVIORAL"},{"name":"Playlist 5","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3607,"nct_id":"NCT07607938","title":"Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT07607938","tracker_url":"publication.php?id=3607","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2026-09","primary_completion_date":"2030-08-01","completion_date":"2030-09-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Anhedonia","Emotional Blunting"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3600,"nct_id":"NCT06943573","title":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial","sponsor":"Lakshmi N Yatham","registry_url":"https://clinicaltrials.gov/study/NCT06943573","tracker_url":"publication.php?id=3600","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-15","start_date":"2026-06-15","primary_completion_date":"2028-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Bipolar II Depression"],"interventions":[{"name":"psilocybin (25 mg)","type":"DRUG"},{"name":"psilocybin 1mg micro-dose","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b080767d21c0ebe8aea0aba1c3f1a88355bed0e01997cb41cb5704abd0b086dc","facility":"Djavad Mowafaghian Centre for Brain Health","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"aa8f99cb753e6ee68d3c63b2cdb1b7e7d90b1680cb84bc239d625d80bd4e6c8b","facility":"Department of Psychiatry, University of Ottawa, The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ab54d44984a52b7a2aba12f9808b881d3f2fa4a702669885a0a10983ba498e39","facility":"Department of Psychiatry, University of Toronto, University Health Network,","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3525,"nct_id":"NCT07565493","title":"Psilocybin Administration With 5-HT1a Blockade","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07565493","tracker_url":"publication.php?id=3525","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-14","start_date":"2026-08-12","primary_completion_date":"2028-06-15","completion_date":"2028-06-15","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":18,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Pindolol","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3684,"nct_id":"NCT06200155","title":"TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT06200155","tracker_url":"publication.php?id=3684","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-11","start_date":"2024-04-16","primary_completion_date":"2026-12-31","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":48,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Depression, Anxiety","Psilocybin-Assisted Psychotherapy","Advanced Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"3a46b1d6e7fd8e6d4ac3522c52ea258b11d52f64ed81a85f442fdb36db5182f6","facility":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3479,"nct_id":"NCT06615908","title":"A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT06615908","tracker_url":"publication.php?id=3479","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-09","start_date":"2025-05-27","primary_completion_date":"2027-06-30","completion_date":"2027-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Persisting Symptoms After Concussion"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3452,"nct_id":"NCT07386730","title":"A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease","sponsor":"Jennifer Mitchell","registry_url":"https://clinicaltrials.gov/study/NCT07386730","tracker_url":"publication.php?id=3452","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-09-09","start_date":"2026-06-01","primary_completion_date":"2030-02","completion_date":"2030-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Anhedonia in Healthy Volunteers","Older Adults (50-90 Years)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Dextromethorphan (DXM)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"52bc2180526f10b62a5aca748b84f9b3b723aee40e4b7ba311fbe63f85e74ca8","facility":"University of California San Francisco, Sandler Neuroscience Building","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3604,"nct_id":"NCT04123314","title":"Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT04123314","tracker_url":"publication.php?id=3604","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2021-03-24","primary_completion_date":"2027-06-30","completion_date":"2027-09-30","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depressive Symptoms","Depression","Alzheimer Disease","Mild Cognitive Impairment"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3590,"nct_id":"NCT06355414","title":"Psilocybin and Affective Function in Chronic Lower Back Pain Depression","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06355414","tracker_url":"publication.php?id=3590","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-04-22","primary_completion_date":"2026-12-30","completion_date":"2026-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Low-back Pain","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Methylphenidate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3552,"nct_id":"NCT06989957","title":"Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06989957","tracker_url":"publication.php?id=3552","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2025-09-17","primary_completion_date":"2028-08","completion_date":"2029-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Posttraumatic Stress Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"MDMA","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3436,"nct_id":"NCT06430541","title":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission","sponsor":"University of Colorado, Denver","registry_url":"https://clinicaltrials.gov/study/NCT06430541","tracker_url":"publication.php?id=3436","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-04","start_date":"2024-11-21","primary_completion_date":"2026-12","completion_date":"2028-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Breast Cancer","Ovarian Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d73c96f237ac68fbda3d911e4b1f4df70d78bffe439fcbd3af6fdd7e0b5b445","facility":"Outpatient CTRC","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"26536ff41048bd47e18a2ae19bf7955b33e3305e2417d2a442cc3e762d6f37db","facility":"University of Colorado Cancer Center","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192}],"countries":["United States"]},{"id":3587,"nct_id":"NCT06349083","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06349083","tracker_url":"publication.php?id=3587","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-09-01","primary_completion_date":"2030-05","completion_date":"2030-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Inactive Placebo","type":"OTHER"},{"name":"Supportive therapy sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3558,"nct_id":"NCT06768944","title":"The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT06768944","tracker_url":"publication.php?id=3558","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-09-02","start_date":"2026-05-15","primary_completion_date":"2027-12","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"OTHER","masking":"QUADRUPLE"},"conditions":["Investigating the Importance of the Subjective Psychedelic Experience"],"interventions":[{"name":"Psilocybin high-dose","type":"DRUG"},{"name":"Psilocybin low-dose","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]},{"id":3522,"nct_id":"NCT06814522","title":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]","sponsor":"University of California, San Diego","registry_url":"https://clinicaltrials.gov/study/NCT06814522","tracker_url":"publication.php?id=3522","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2026-09-02","start_date":"2025-01-13","primary_completion_date":"2028-06","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Burnout","Burnout, Healthcare Workers"],"interventions":[{"name":"Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate","type":"DRUG"},{"name":"Real-time Biofeedback","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"2e7548466e831b567e38ef1e8fdd7baae3817e9b4e2a89bc35dca43d64edbecb","facility":"UC San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472}],"countries":["United States"]},{"id":3540,"nct_id":"NCT07211438","title":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT07211438","tracker_url":"publication.php?id=3540","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-21","start_date":"2026-07-03","primary_completion_date":"2028-07","completion_date":"2029-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Treatment-Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"61ce79cfaa08fedbb10711df8d7c73a357fd5df0b146e4b4ff109a1f1ba7fd39","facility":"Toronto Western Hospital (University Health Network)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3626,"nct_id":"NCT07169747","title":"The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults","sponsor":"Region Skane","registry_url":"https://clinicaltrials.gov/study/NCT07169747","tracker_url":"publication.php?id=3626","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-08-14","start_date":"2026-07-20","primary_completion_date":"2027-10-01","completion_date":"2027-10-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"277ec95effb37a499f97d6fb82da461e2d3790bb840eb8be0d307666a1a93593","facility":"Psykiatrikliniken, Baravägen 1","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001}],"countries":["Sweden"]},{"id":3472,"nct_id":"NCT07226232","title":"A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans","sponsor":"VA Office of Research and Development","registry_url":"https://clinicaltrials.gov/study/NCT07226232","tracker_url":"publication.php?id=3472","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-14","start_date":"2026-08-03","primary_completion_date":"2030-12-02","completion_date":"2031-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":240,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1094674cfb576eb3aba9c610abfa1ec8007d88c3fc30323de895b78b257dc9ca","facility":"Birmingham VA Medical Center, Birmingham, AL","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"36ded30328be4e5de016f706a8efcb9e2ce3181d513bae1f031f8c88931e15dd","facility":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","lat":33.20984,"lon":-87.56917},{"key":"673eee709be8746b7b99358264e9a830cab9eff575766127a823456961139800","facility":"VA Portland Health Care System, Portland, OR","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"5bc04aa77be1370761183e8a64f2c2e1129ef67efc98b5f6610da73065ccb37c","facility":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"cf2d4c3f9eed8457b9a5ca21d741ba54a1b036d130efd17e977384b0d89a5133","facility":"VA Puget Sound Health Care System Seattle Division, Seattle, WA","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207}],"countries":["United States"]},{"id":3678,"nct_id":"NCT06692192","title":"Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT06692192","tracker_url":"publication.php?id=3678","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-08-13","start_date":"2025-08-07","primary_completion_date":"2027-12","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psilocybin"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Midazolam","type":"DRUG"},{"name":"Saline","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"72b096fd9021c9bfd550d9d949b2594137c212c14110e7c00e66d39b5f8101eb","facility":"UW School of Medicine and Public Health","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3562,"nct_id":"NCT06899165","title":"Processing Intergenerational Trauma With Psilocybin-Assisted Therapy","sponsor":"Rachel Yehuda","registry_url":"https://clinicaltrials.gov/study/NCT06899165","tracker_url":"publication.php?id=3562","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2026-08-28","primary_completion_date":"2029-05-31","completion_date":"2030-01-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Psychological Stress","Depression","Anxiety"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Integration sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3539,"nct_id":"NCT06247839","title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","sponsor":"Sharmin Ghaznavi","registry_url":"https://clinicaltrials.gov/study/NCT06247839","tracker_url":"publication.php?id=3539","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-13","start_date":"2024-09-10","primary_completion_date":"2028-06-30","completion_date":"2028-06-30","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ae85e9f90db4bd1845b2a9817e008d4a625ffc046123c8a22344695349c7e230","facility":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","lat":42.377870000000001,"lon":-71.061999999999998}],"countries":["United States"]},{"id":3674,"nct_id":"NCT06801041","title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","sponsor":"M.D. Anderson Cancer Center","registry_url":"https://clinicaltrials.gov/study/NCT06801041","tracker_url":"publication.php?id=3674","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2025-05-23","primary_completion_date":"2027-03-31","completion_date":"2029-03-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Depression","Anxiety","Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3581,"nct_id":"NCT06706232","title":"Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","sponsor":"The University of Texas Health Science Center, Houston","registry_url":"https://clinicaltrials.gov/study/NCT06706232","tracker_url":"publication.php?id=3581","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-12","start_date":"2025-07-07","primary_completion_date":"2027-08","completion_date":"2027-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Bipolar II Disorder","Depression, Bipolar","Suicidality"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Therapeutic Support","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"da2bda06c1b463bdcf59130477fd36b92915811ee4ac0f0c25eafb7329fb0cb9","facility":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3426,"nct_id":"NCT06969170","title":"A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder","sponsor":"Claudio N Soares","registry_url":"https://clinicaltrials.gov/study/NCT06969170","tracker_url":"publication.php?id=3426","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-12","start_date":"2025-05-16","primary_completion_date":"2027-12-31","completion_date":"2028-12-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"QUADRUPLE"},"conditions":["Generalized Anxiety Disorder (GAD)"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"5e54e3832bb9c4f6cddd3eeefc9951bb04903d8e26aedf819b29aa11a2e0c418","facility":"Kingston General Health Research Institute","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3523,"nct_id":"NCT06656702","title":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06656702","tracker_url":"publication.php?id=3523","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-11","start_date":"2025-04-09","primary_completion_date":"2027-01-30","completion_date":"2027-07-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3642,"nct_id":"NCT06512194","title":"An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)","sponsor":"Charles Raison","registry_url":"https://clinicaltrials.gov/study/NCT06512194","tracker_url":"publication.php?id=3642","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2025-05-13","primary_completion_date":"2029-05","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":141,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Sham taVNS","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942}],"countries":["United States"]},{"id":3531,"nct_id":"NCT07251491","title":"Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","sponsor":"James J. Peters Veterans Affairs Medical Center","registry_url":"https://clinicaltrials.gov/study/NCT07251491","tracker_url":"publication.php?id=3531","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-10","start_date":"2026-08-06","primary_completion_date":"2028-03-01","completion_date":"2028-03-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Spinal Cord Injury","Depression - Major Depressive Disorder","Veteran"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1b2819d4a8ca62168bb131d84bf5a2039f0800c02db6394dd76a4e6af80edf2c","facility":"James J. Peters Department of Veterans Affairs Medical Center","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002}],"countries":["United States"]},{"id":3561,"nct_id":"NCT06455293","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sponsor":"Joshua Woolley, MD, PhD","registry_url":"https://clinicaltrials.gov/study/NCT06455293","tracker_url":"publication.php?id=3561","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-08-07","start_date":"2024-08-19","primary_completion_date":"2027-06","completion_date":"2028-06","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Parkinson Disease","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3507,"nct_id":"NCT06233344","title":"An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy","sponsor":"University of Southern California","registry_url":"https://clinicaltrials.gov/study/NCT06233344","tracker_url":"publication.php?id=3507","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-06","start_date":"2025-07-30","primary_completion_date":"2027-08","completion_date":"2028-08","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"NONE"},"conditions":["Mental Health"],"interventions":[{"name":"Psilocybin plus mindfulness training","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"fe41ad3987d6de6fe68c69a1ba7b8083c49c8f7f3ed503bb29759b163851e03c","facility":"Univeristy of Southern California Brain and Creativity Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3437,"nct_id":"NCT06001749","title":"Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer","sponsor":"Yvan Beaussant, MD, MSci","registry_url":"https://clinicaltrials.gov/study/NCT06001749","tracker_url":"publication.php?id=3437","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-08-05","start_date":"2024-09-23","primary_completion_date":"2026-10-01","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Opioid-Related Disorders","Pain Management","Pain Management and Care","Advanced Cancer","Advanced Cancers"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977}],"countries":["United States"]},{"id":3565,"nct_id":"NCT07118332","title":"Psilocybin as a Treatment for Chronic Pain in Smokers","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT07118332","tracker_url":"publication.php?id=3565","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-08-03","start_date":"2026-07-06","primary_completion_date":"2027-10-01","completion_date":"2027-12-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Smokers With Chronic Pain"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1dd82fd9cc6558717200ae66d13a24d08c805492d49f67b2d8f9edc800d2c261","facility":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":5760,"nct_id":"NCT07737054","title":"Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder","sponsor":"Tel-Aviv Sourasky Medical Center","registry_url":"https://clinicaltrials.gov/study/NCT07737054","tracker_url":"publication.php?id=5760","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-30","start_date":"2025-07-22","primary_completion_date":"2026-12-01","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":13,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post-Traumatic Stress Disorder, PTSD"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Trauma-Focused Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"a9c873ac063d6e120c29fe3a990563df65d56f36d533e4becc50b462afacd39c","facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","region":"","country":"Israel","lat":32.080880000000001,"lon":34.780569999999997}],"countries":["Israel"]},{"id":3647,"nct_id":"NCT06512220","title":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06512220","tracker_url":"publication.php?id=3647","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-07-30","start_date":"2025-04-21","primary_completion_date":"2027-04","completion_date":"2027-09","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3591,"nct_id":"NCT06518720","title":"Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial","sponsor":"Centre for Addiction and Mental Health","registry_url":"https://clinicaltrials.gov/study/NCT06518720","tracker_url":"publication.php?id=3591","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-30","start_date":"2025-04-01","primary_completion_date":"2027-03","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression","Chronic Pain"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3542,"nct_id":"NCT05866471","title":"Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT05866471","tracker_url":"publication.php?id=3542","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-29","start_date":"2025-01-27","primary_completion_date":"2027-11","completion_date":"2028-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":108,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy","Psychedelic Experiences","Vagus Nerve Stimulation"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Transcutaneous auricular Vagus Nerve Stimulation (taVNS)","type":"DEVICE"},{"name":"Psychosocial Support Alone","type":"BEHAVIORAL"},{"name":"Sham taVNS","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":5755,"nct_id":"NCT07732166","title":"Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.","sponsor":"Pontifícia Universidade Católica do Rio de Janeiro","registry_url":"https://clinicaltrials.gov/study/NCT07732166","tracker_url":"publication.php?id=5755","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-28","start_date":"2026-04-01","primary_completion_date":"2027-08-01","completion_date":"2027-12-01","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"TRIPLE"},"conditions":["Healthy Adults"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Niacin 100 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"56dbd951047579f5e7cb6365abb06b654904e94f48585c22b28b8f01d8930412","facility":"Centro de Pesquisas Matteo Ricci","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","lat":-22.906420000000001,"lon":-43.182229999999997}],"countries":["Brazil"]},{"id":3710,"nct_id":"NCT07347405","title":"A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","sponsor":"Francisco A Moreno","registry_url":"https://clinicaltrials.gov/study/NCT07347405","tracker_url":"publication.php?id=3710","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-07-23","start_date":"2026-05-18","primary_completion_date":"2028-12-31","completion_date":"2029-01-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Obsessive-Compulsive Disorder"],"interventions":[{"name":"Psilocybin 10 mg","type":"DRUG"},{"name":"Psilocybin 20 mg","type":"DRUG"},{"name":"Psilocybin 30 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648}],"countries":["United States"]},{"id":3707,"nct_id":"NCT05301608","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05301608","tracker_url":"publication.php?id=3707","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2022-03-03","primary_completion_date":"2026-12-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3566,"nct_id":"NCT06820723","title":"A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety","sponsor":"Ohio State University","registry_url":"https://clinicaltrials.gov/study/NCT06820723","tracker_url":"publication.php?id=3566","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-23","start_date":"2026-08-01","primary_completion_date":"2028-09","completion_date":"2028-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Depression","Anxiety","Major Depressive Disorder"],"interventions":[{"name":"CYB003","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3691,"nct_id":"NCT06067737","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06067737","tracker_url":"publication.php?id=3691","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-17","start_date":"2024-02-08","primary_completion_date":"2028-07","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":5722,"nct_id":"NCT07703722","title":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial","sponsor":"Khyber Medical University Peshawar","registry_url":"https://clinicaltrials.gov/study/NCT07703722","tracker_url":"publication.php?id=5722","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-14","start_date":"2026-04-01","primary_completion_date":"2027-10-22","completion_date":"2027-11-22","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Major Depressive Disorder","Post-Traumatic Stress Disorder (PTSD)"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Structured Integrated Reframing Therapy (SIRT)","type":"BEHAVIORAL"},{"name":"Selective Serotonin Reuptake Inhibitor (SSRI)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e80ae31010614821a2c0251a43cb105eb5afdf4210df2d02fbca62249b4812cb","facility":"Institute of Health Science, Khyber Medical University","city":"Islamabad","region":"Capital","country":"Pakistan","lat":33.72148,"lon":73.043289999999999},{"key":"482052fef0467a4bb441cf6e5d88301072e19c45a3a032776b1d48bce47e7a68","facility":"Hayatabad Medical Complex Peshawar","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"54a0606875858be17f5c6f12f6ec10397681ed8e3c5b816b0964b25c06587ac1","facility":"Khyber Medical University","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002}],"countries":["Pakistan"]},{"id":3648,"nct_id":"NCT06464367","title":"Mechanistic Studies of Psilocybin in Headache Disorders","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06464367","tracker_url":"publication.php?id=3648","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-13","start_date":"2025-05-19","primary_completion_date":"2027-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"QUADRUPLE"},"conditions":["Migraine"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004}],"countries":["United States"]},{"id":3502,"nct_id":"NCT07063862","title":"PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial","sponsor":"Bruyère Health Research Institute.","registry_url":"https://clinicaltrials.gov/study/NCT07063862","tracker_url":"publication.php?id=3502","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-07-10","start_date":"2026-01-28","primary_completion_date":"2027-08","completion_date":"2027-09","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":120,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Psychological Distress"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"104bc03ef1be3eb283fc88bf5fce3e5ff6c85007bff327791c7a04846f88d35a","facility":"William Osler Health System","city":"Brampton","region":"Ontario","country":"Canada","lat":43.683410000000002,"lon":-79.766329999999996},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"6f7cb2e1921867a894d4f688041519f8adcacf7b68acf4348e2e37c6661d4cdf","facility":"St. Joseph's Healthcare","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003},{"key":"f934fa0d3d51d6c774793a28fc64efcf90b8e28198269a1250a0c3f99f3ed6f9","facility":"South Lake Regional Health Centre","city":"Newmarket","region":"Ontario","country":"Canada","lat":44.050109999999997,"lon":-79.466309999999993},{"key":"25666f03708722f78f57cf2a417d211304fca135b845052bac716c024043384f","facility":"Bruyere Health","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"191b97d23002f5fc0aef25ec189e10d4d9cfe3306186fed0ac8629e958a94280","facility":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ef9bc15ff41fe07277a1de400fafab1b05a763305b6e78adf15926ff3f12ea42","facility":"McGill University Health Centre","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005}],"countries":["Canada"]},{"id":3432,"nct_id":"NCT05265546","title":"Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","sponsor":"University of California, Berkeley","registry_url":"https://clinicaltrials.gov/study/NCT05265546","tracker_url":"publication.php?id=3432","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-10","start_date":"2024-03-08","primary_completion_date":"2028-12-31","completion_date":"2028-12-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Perception Disorders"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275}],"countries":["United States"]},{"id":3431,"nct_id":"NCT06810310","title":"Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder","sponsor":"University of Pennsylvania","registry_url":"https://clinicaltrials.gov/study/NCT06810310","tracker_url":"publication.php?id=3431","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-09","start_date":"2025-12-22","primary_completion_date":"2027-05-01","completion_date":"2027-05-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"psilocybin (low dose)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995}],"countries":["United States"]},{"id":3652,"nct_id":"NCT04161066","title":"Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation","sponsor":"University of Wisconsin, Madison","registry_url":"https://clinicaltrials.gov/study/NCT04161066","tracker_url":"publication.php?id=3652","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-07","start_date":"2021-01-13","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin with facilitated counseling","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998}],"countries":["United States"]},{"id":3603,"nct_id":"NCT06160284","title":"Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06160284","tracker_url":"publication.php?id=3603","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-07","last_update_date":"2026-07-07","start_date":"2025-05-28","primary_completion_date":"2027-01","completion_date":"2027-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"NONE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3662,"nct_id":"NCT07638553","title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sponsor":"Centre Hospitalier Universitaire de Nīmes","registry_url":"https://clinicaltrials.gov/study/NCT07638553","tracker_url":"publication.php?id=3662","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-06-30","primary_completion_date":"2030-06","completion_date":"2030-06","study_type":"INTERVENTIONAL","phases":["PHASE3"],"enrollment":{"count":172,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Alcohol Use Disorder","Depressive Sympotoms","Psilocybin"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Psilocybin (low dose)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003}],"countries":["France"]},{"id":3547,"nct_id":"NCT06902974","title":"A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","sponsor":"Sunstone Medical","registry_url":"https://clinicaltrials.gov/study/NCT06902974","tracker_url":"publication.php?id=3547","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-07-01","start_date":"2026-05-23","primary_completion_date":"2027-11","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":70,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Post Traumatic Stress Disorder","PTSD"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3494,"nct_id":"NCT05452772","title":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT05452772","tracker_url":"publication.php?id=3494","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-29","start_date":"2023-11-01","primary_completion_date":"2026-12","completion_date":"2027-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":66,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Tobacco Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3560,"nct_id":"NCT07104916","title":"A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)","sponsor":"Anthony P King","registry_url":"https://clinicaltrials.gov/study/NCT07104916","tracker_url":"publication.php?id=3560","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-25","start_date":"2026-07-01","primary_completion_date":"2029-09","completion_date":"2029-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Post Traumatic Stress Disorder","Depression - Major Depressive Disorder"],"interventions":[{"name":"Psilocybin + MBCT therapy","type":"COMBINATION_PRODUCT"},{"name":"Active Comparator: Psilocybin with Support Only","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin"],"sites":[{"key":"dab33405eff5190f72da59b78efc1f976cb32567ca0ed993e0fa62358b51185e","facility":"The Ohio State University Medical Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3650,"nct_id":"NCT07048743","title":"Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial","sponsor":"University Health Network, Toronto","registry_url":"https://clinicaltrials.gov/study/NCT07048743","tracker_url":"publication.php?id=3650","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-23","start_date":"2025-07-16","primary_completion_date":"2027-12-02","completion_date":"2027-12-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Caregiver Distress"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"c2b8ac7cbe1dfe7dfd4a496dfe7196accedd01cd287918d4f9a3f24cacfa9649","facility":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3637,"nct_id":"NCT06724289","title":"Psilocybin-Assisted Therapy for Prolonged Grief","sponsor":"University of Virginia","registry_url":"https://clinicaltrials.gov/study/NCT06724289","tracker_url":"publication.php?id=3637","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-23","start_date":"2026-03-24","primary_completion_date":"2027-08","completion_date":"2027-08","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Prolonged Grief Disorder"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Functional Magnetic Resonance Imaging (fMRI)","type":"DIAGNOSTIC_TEST"}],"substances":["psilocybin"],"sites":[{"key":"7d95aada95625af597e7f99db1d1499ad1edcc4815ba129bc332e93fab4f316e","facility":"University of Virginia","city":"Charlottesville","region":"Virginia","country":"United States","lat":38.029310000000002,"lon":-78.476680000000002}],"countries":["United States"]},{"id":3483,"nct_id":"NCT06626139","title":"2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers","sponsor":"Robin Carhart-Harris, PhD, MA","registry_url":"https://clinicaltrials.gov/study/NCT06626139","tracker_url":"publication.php?id=3483","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-06","last_update_date":"2026-06-04","start_date":"2024-10-20","primary_completion_date":"2027-11-30","completion_date":"2028-11-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":120,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"BASIC_SCIENCE","masking":"DOUBLE"},"conditions":["Healthy Participants With Lower-than-average Mental Well-being"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Context 1","type":"BEHAVIORAL"},{"name":"Context 2","type":"BEHAVIORAL"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"198d5bb2b7293acb85f77709d851433288e2bd94aaa3b81634c72028f5024289","facility":"UCSF Mission Bay","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3614,"nct_id":"NCT07506395","title":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","sponsor":"University of New Mexico","registry_url":"https://clinicaltrials.gov/study/NCT07506395","tracker_url":"publication.php?id=3614","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-22","start_date":"2026-05-01","primary_completion_date":"2027-05-01","completion_date":"2028-05-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114}],"countries":["United States"]},{"id":3606,"nct_id":"NCT07216404","title":"Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)","sponsor":"Alan Davis","registry_url":"https://clinicaltrials.gov/study/NCT07216404","tracker_url":"publication.php?id=3606","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-05","last_update_date":"2026-05-14","start_date":"2026-01-01","primary_completion_date":"2027-10-31","completion_date":"2027-10-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"SUPPORTIVE_CARE","masking":"NONE"},"conditions":["Lung Non-Small Cell Carcinoma","Unipolar Depression"],"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Counseling","type":"OTHER"},{"name":"Interview","type":"OTHER"},{"name":"Psilocybin","type":"DRUG"},{"name":"Survey Administration","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"d57ba16f21b5e5513a5f85825fdee40ef908d80b41bdf65f0b98dc075445577b","facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879}],"countries":["United States"]},{"id":3570,"nct_id":"NCT06782724","title":"The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.","sponsor":"University Medical Center Groningen","registry_url":"https://clinicaltrials.gov/study/NCT06782724","tracker_url":"publication.php?id=3570","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-05-08","start_date":"2025-07-01","primary_completion_date":"2027-01-01","completion_date":"2028-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":108,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["COPD (Chronic Obstructive Pulmonary Disease)","ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"815dca1c51560a2771c70b436758dad26e0e7113577a98422d68f884f890d354","facility":"National Institute of Mental Health","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"34a79f541cea47ad7b374bfde6da99960b2120ed088ec92eaa3df41e96eb7390","facility":"Bispebjerg Hospital","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"27d7b4df35cb1e0b4d4349418e100597b52afe044578477ac7a1e36059b373ba","facility":"University Medical Center Groningen","city":"Groningen","region":"Provincie Groningen","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"0aaa8840c6965661f46de84dc613d0842e14dbd41f5597c5ec01c47dcbaabd26","facility":"Champalimaud Foundation","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008}],"countries":["Czechia","Denmark","Netherlands","Portugal"]},{"id":3509,"nct_id":"NCT05883540","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05883540","tracker_url":"publication.php?id=3509","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-29","start_date":"2024-06-09","primary_completion_date":"2027-09","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress"],"interventions":[{"name":"Lysergic Acid Diethylamide Tartrate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3578,"nct_id":"NCT06319378","title":"CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","registry_url":"https://clinicaltrials.gov/study/NCT06319378","tracker_url":"publication.php?id=3578","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-13","start_date":"2024-04-19","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["MDD"],"interventions":[{"name":"psilocybin 25 mg sod","type":"DRUG"},{"name":"psilocybin 1 mg sod","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"5f5211b90f32857d4a2b3783ed0a8d299123b97980aecac0dc9fd0a8439396d7","facility":"region Västra Götaland","city":"Gothenburg","region":"Göteborg","country":"Sweden","lat":57.707160000000002,"lon":11.96679},{"key":"56f6973050dae2540f6877689b3512d938f70ee52e4bd51ebc6542c3a6adaa89","facility":"Norra Stockholms Psykiatri","city":"Stockholm","region":"Stockholm County","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"384faadacad1af176bc642c675eb5c7bdc2ad01c26ea770b0702143798b59dfa","facility":"Psykiatriska Kliniken, Akademiska Sjukhuset","city":"Uppsala","region":"Uppsala County","country":"Sweden","lat":59.858820000000001,"lon":17.63889},{"key":"046953804b0a225af99cd7bd152e5969b25e38978f43961e75862c8ef2f53fc5","facility":"Örebro sjukhus","city":"Örebro","region":"Örebro County","country":"Sweden","lat":59.274120000000003,"lon":15.2066}],"countries":["Sweden"]},{"id":3663,"nct_id":"NCT06072898","title":"Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression","sponsor":"Sunnybrook Health Sciences Centre","registry_url":"https://clinicaltrials.gov/study/NCT06072898","tracker_url":"publication.php?id=3663","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-30","start_date":"2025-05-28","primary_completion_date":"2028-05","completion_date":"2029-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"QUADRUPLE"},"conditions":["Depressive Disorder","Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Microcrystalline cellulose","type":"OTHER"},{"name":"Supportive psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d8875f7f4d4e3f36b2235d0201354748ba8de08e94380e3b3cb5c9f3cfca0d9e","facility":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3696,"nct_id":"NCT06898606","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","sponsor":"Federal University of Latin American Integration","registry_url":"https://clinicaltrials.gov/study/NCT06898606","tracker_url":"publication.php?id=3696","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-27","start_date":"2024-09-05","primary_completion_date":"2026-08-20","completion_date":"2026-11-20","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Depressive Disorder"],"interventions":[{"name":"Psilocybin and Psilocyn","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Psychotherapy-assisted session","type":"BEHAVIORAL"},{"name":"Fluoxetine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0baab4fede4fc6054da41261b4cd831dfa37af046f4a5adc5c2912ab388dff0e","facility":"Federal University of Latin American Integration","city":"Foz do Iguaçu","region":"Paraná","country":"Brazil","lat":-25.547779999999999,"lon":-54.588059999999999}],"countries":["Brazil"]},{"id":3447,"nct_id":"NCT07490353","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial","sponsor":"Medical University of Vienna","registry_url":"https://clinicaltrials.gov/study/NCT07490353","tracker_url":"publication.php?id=3447","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-24","start_date":"2025-11-01","primary_completion_date":"2028-05-31","completion_date":"2028-05-31","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":85,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Depression - Major Depressive Disorder","Anhedonia"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"},{"name":"Risperidone 1 MG","type":"DRUG"},{"name":"MRI","type":"DIAGNOSTIC_TEST"}],"substances":["psilocybin"],"sites":[{"key":"e1f0adb91f843c24eebaa1127eb64810250131187c9a0be296d3c4b271f3acb7","facility":"Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry","city":"Vienna","region":"State of Vienna","country":"Austria","lat":48.208489999999998,"lon":16.37208}],"countries":["Austria"]},{"id":3643,"nct_id":"NCT06660381","title":"Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06660381","tracker_url":"publication.php?id=3643","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2024-11-08","primary_completion_date":"2026-11","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Cannabis Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3641,"nct_id":"NCT06818994","title":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study","sponsor":"Gustavo Vazquez","registry_url":"https://clinicaltrials.gov/study/NCT06818994","tracker_url":"publication.php?id=3641","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2026-04-01","primary_completion_date":"2027-06-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Demoralization","Safety"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3517,"nct_id":"NCT05068791","title":"Psilocybin-facilitated Treatment for Chronic Pain","sponsor":"University of Alabama at Birmingham","registry_url":"https://clinicaltrials.gov/study/NCT05068791","tracker_url":"publication.php?id=3517","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2023-11-01","primary_completion_date":"2026-12-31","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Fibromyalgia, Primary"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Dextromethorphan","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"57b51432bd54eead1665bf308d75c58452112099cecfea39a38a9a4ae8d6e95d","facility":"UAB Beacon Tower","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3473,"nct_id":"NCT06442423","title":"Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study","sponsor":"Yale University","registry_url":"https://clinicaltrials.gov/study/NCT06442423","tracker_url":"publication.php?id=3473","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2024-10-17","primary_completion_date":"2027-12","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Transdiagnostic","Depression - Major Depressive Disorder","Anxiety","PTSD Symptoms","PTSD","Substance Use","Substance Use Disorder (SUD)","OCD"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005}],"countries":["United States"]},{"id":3616,"nct_id":"NCT07072728","title":"A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.","sponsor":"Psyence Australia Pty Ltd","registry_url":"https://clinicaltrials.gov/study/NCT07072728","tracker_url":"publication.php?id=3616","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-03-03","start_date":"2025-10-01","primary_completion_date":"2026-12-30","completion_date":"2027-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":87,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Adjustment Disorder","Adjustment Disorder With Anxious Mood","Cancer","Cancer Cachexia","Cancer of Endometrium","Cancer of Kidney","Cancer of Prostate","Cancer of the Breast","Cancer of Stomach","Cancer Melanoma Skin","Cancer Pancreas"],"interventions":[{"name":"Psilocybin therapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"60b561826ea1087d0a6075e09763aebb8728c09f0183a3d029f1558c69e69bd3","facility":"Mind Medicine Australia Clinic","city":"Abbotsford","region":"Victoria","country":"Australia","lat":-37.799999999999997,"lon":145},{"key":"bc24127b43b0f70565a09f33f689e5c1c9ef6f31ba136c7650ba0fd99b8289cb","facility":"Paratus Clinical Research Melbourne","city":"Northcote","region":"Victoria","country":"Australia","lat":-37.766669999999998,"lon":145},{"key":"adfbd3436ba3de0148122053ef79072e74006b058256ba9b8f2d0a035013fd6b","facility":"Empax Centre","city":"Leederville","region":"Western Australia","country":"Australia","lat":-31.93628,"lon":115.8419}],"countries":["Australia"]},{"id":3458,"nct_id":"NCT06399263","title":"Study of Psilocybin for Anorexia in Young Adults","sponsor":"Marissa Raymond-Flesch, MD, MPH","registry_url":"https://clinicaltrials.gov/study/NCT06399263","tracker_url":"publication.php?id=3458","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-03-03","start_date":"2024-11-18","primary_completion_date":"2029-11","completion_date":"2029-11","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Anorexia Nervosa"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Preparation and Integration Sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942}],"countries":["United States"]},{"id":3551,"nct_id":"NCT06772753","title":"Investigation of Psychedelic Effects in Psychoactive Substances","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT06772753","tracker_url":"publication.php?id=3551","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-23","start_date":"2025-02-05","primary_completion_date":"2027-06","completion_date":"2027-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Psychedelic Effects in Healthy Volunteers"],"interventions":[{"name":"Placebo","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"},{"name":"Dextromethorphan (DXM)","type":"DRUG"},{"name":"Dimethyltryptamine (DMT)","type":"DRUG"},{"name":"Methylenedioxymethamphetamine (MDMA)","type":"DRUG"},{"name":"Tetrahydrocannabinol (THC)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3425,"nct_id":"NCT07053917","title":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","sponsor":"Johns Hopkins University","registry_url":"https://clinicaltrials.gov/study/NCT07053917","tracker_url":"publication.php?id=3425","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-02","last_update_date":"2026-02-13","start_date":"2026-02-09","primary_completion_date":"2027-02","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and/or Hemiparesis Following Stroke","Middle Cerebral Artery Stroke"],"interventions":[{"name":"Psilocybin (Usona Institute)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998}],"countries":["United States"]},{"id":3514,"nct_id":"NCT07281352","title":"Psilocybin-Assisted Cognitive Behavioral Therapy for Depression","sponsor":"University of California, Los Angeles","registry_url":"https://clinicaltrials.gov/study/NCT07281352","tracker_url":"publication.php?id=3514","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-02-12","start_date":"2026-01-05","primary_completion_date":"2027-11-30","completion_date":"2027-11-30","study_type":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"enrollment":{"count":50,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"SINGLE"},"conditions":["Major Depressive Diorder"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"cognitive behavioral therapy","type":"BEHAVIORAL"},{"name":"Minimal supportive therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368}],"countries":["United States"]},{"id":3690,"nct_id":"NCT07079930","title":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","sponsor":"Hadassah Medical Organization","registry_url":"https://clinicaltrials.gov/study/NCT07079930","tracker_url":"publication.php?id=3690","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-07","last_update_date":"2026-02-05","start_date":"2025-12-11","primary_completion_date":"2026-11","completion_date":"2027-02","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Healthy Volunteers"],"interventions":[{"name":"Psilocybin and D-Serine","type":"DRUG"},{"name":"Physical Examination","type":"DIAGNOSTIC_TEST"},{"name":"Vital signs","type":"DIAGNOSTIC_TEST"},{"name":"ECG test","type":"DIAGNOSTIC_TEST"},{"name":"Comprehensive Blood Panel","type":"DIAGNOSTIC_TEST"},{"name":"Complete Blood Count","type":"DIAGNOSTIC_TEST"},{"name":"Urinalysis","type":"DIAGNOSTIC_TEST"},{"name":"Urine Toxicology Screen","type":"DIAGNOSTIC_TEST"},{"name":"A pregnancy Urine test","type":"DIAGNOSTIC_TEST"},{"name":"Electroencephalogram","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Amino Acid Levels","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Inflammation Markers","type":"DIAGNOSTIC_TEST"},{"name":"Plasma Brain-Derived Neurotrophic Facto","type":"DIAGNOSTIC_TEST"},{"name":"Mini International Neuropsychiatric Interview","type":"OTHER"},{"name":"Family Psychiatric History Assessment","type":"OTHER"},{"name":"Beck Depression Inventory","type":"OTHER"},{"name":"State-Trait Anxiety Inventory","type":"OTHER"},{"name":"Profile of Mood States","type":"BEHAVIORAL"},{"name":"Subjective Units of Distress Scale","type":"BEHAVIORAL"},{"name":"Five-Dimensional Altered States of Consciousness questionnaire","type":"OTHER"},{"name":"Integration","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"429fe69d07db5cabcda31c9415fb3b7bade24763ccdfea22c895d8c381fdd472","facility":"Hadassah Medical Organization, Jerusalem, Israel","city":"Jerusalem","region":"","country":"Israel","lat":31.76904,"lon":35.216329999999999}],"countries":["Israel"]},{"id":3673,"nct_id":"NCT06796062","title":"A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06796062","tracker_url":"publication.php?id=3673","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-01-23","start_date":"2025-12-17","primary_completion_date":"2029-02","completion_date":"2029-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":480,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002}],"countries":["United States"]},{"id":3703,"nct_id":"NCT06888128","title":"The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","sponsor":"Baylor College of Medicine","registry_url":"https://clinicaltrials.gov/study/NCT06888128","tracker_url":"publication.php?id=3703","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-01","last_update_date":"2026-01-22","start_date":"2025-01-30","primary_completion_date":"2026-12-15","completion_date":"2026-12-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["PTSD"],"interventions":[{"name":"Psilocybin 15mg","type":"DRUG"},{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327}],"countries":["United States"]},{"id":3625,"nct_id":"NCT06798636","title":"Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study","sponsor":"Imperial College London","registry_url":"https://clinicaltrials.gov/study/NCT06798636","tracker_url":"publication.php?id=3625","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-12-05","start_date":"2025-10-01","primary_completion_date":"2026-08-31","completion_date":"2026-10-31","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"TRIPLE"},"conditions":["Self Harm"],"interventions":[{"name":"Psilocybin 5 mg with cognitive behavioural therapy intervention","type":"DRUG"},{"name":"Placebo with cognitive behavioural therapy intervention","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3692,"nct_id":"NCT05585229","title":"Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study","sponsor":"University of British Columbia","registry_url":"https://clinicaltrials.gov/study/NCT05585229","tracker_url":"publication.php?id=3692","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-12-04","start_date":"2025-10-27","primary_completion_date":"2026-08-31","completion_date":"2026-08-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Opioid Dependence","Chronic Pain"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ea083ab2fc2ae83a35a58fe8386ef0b69ef14561d64fefb0069b5be4bb994b97","facility":"University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568}],"countries":["Canada"]},{"id":3513,"nct_id":"NCT05398484","title":"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT05398484","tracker_url":"publication.php?id=3513","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2025-12-04","start_date":"2023-05-24","primary_completion_date":"2027-01-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Advanced Cancer"],"interventions":[{"name":"Psilocybin 25 mgs","type":"DRUG"},{"name":"Niacin 100mg","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3444,"nct_id":"NCT06405607","title":"Psilocybin vs Ketamine for Alcohol Use Disorder","sponsor":"University of Iowa","registry_url":"https://clinicaltrials.gov/study/NCT06405607","tracker_url":"publication.php?id=3444","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-28","start_date":"2025-06-12","primary_completion_date":"2028-04","completion_date":"2028-04","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":80,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder","Alcohol Dependence","Alcohol Abuse"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998}],"countries":["United States"]},{"id":3698,"nct_id":"NCT06815653","title":"Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.","sponsor":"University College, London","registry_url":"https://clinicaltrials.gov/study/NCT06815653","tracker_url":"publication.php?id=3698","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-26","start_date":"2025-03-01","primary_completion_date":"2026-03","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"OTHER","masking":"SINGLE"},"conditions":["Healthy"],"interventions":[{"name":"Psilocybin 25mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999}],"countries":["United Kingdom"]},{"id":3681,"nct_id":"NCT06132178","title":"Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder","sponsor":"University of Texas at Austin","registry_url":"https://clinicaltrials.gov/study/NCT06132178","tracker_url":"publication.php?id=3681","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-26","start_date":"2025-01-10","primary_completion_date":"2029-12-31","completion_date":"2030-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment Resistant Depression","MDD","Major Depressive Disorder","Recurrent Depression","Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"},{"name":"Low-dose psilocybin","type":"DRUG"},{"name":"Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment","type":"DEVICE"}],"substances":["psilocybin"],"sites":[{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306}],"countries":["United States"]},{"id":3700,"nct_id":"NCT05403086","title":"Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life","sponsor":"Charles S. Grob, M.D.","registry_url":"https://clinicaltrials.gov/study/NCT05403086","tracker_url":"publication.php?id=3700","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-25","start_date":"2025-01-19","primary_completion_date":"2026-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Demoralization"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]},{"id":3548,"nct_id":"NCT07183748","title":"A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression","sponsor":"Beersheva Mental Health Center","registry_url":"https://clinicaltrials.gov/study/NCT07183748","tracker_url":"publication.php?id=3548","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-08","last_update_date":"2025-11-19","start_date":"2025-12-01","primary_completion_date":"2027-06-01","completion_date":"2028-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin (drug)","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin"],"sites":[{"key":"f6e857b260b7429beba395444fac2f816d9d86eb9ae717988e7a361b734fead7","facility":"Mental Health Center Beer Sheva","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913}],"countries":["Israel"]},{"id":3454,"nct_id":"NCT04882839","title":"Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.","sponsor":"Beersheva Mental Health Center","registry_url":"https://clinicaltrials.gov/study/NCT04882839","tracker_url":"publication.php?id=3454","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-02","last_update_date":"2025-11-19","start_date":"2024-11-25","primary_completion_date":"2026-06-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Obsessive-compulsive Disorder"],"interventions":[{"name":"psychotherapy assisted psilocybin","type":"COMBINATION_PRODUCT"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"5b227dd2e6263d32525d87b3fb390db797275e595c1806af406b57648ac86736","facility":"Beer Sheva Mental Health Center","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913}],"countries":["Israel"]},{"id":3597,"nct_id":"NCT06786325","title":"A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?","sponsor":"Anna Rose Childress, Ph.D.","registry_url":"https://clinicaltrials.gov/study/NCT06786325","tracker_url":"publication.php?id=3597","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-10","last_update_date":"2025-10-29","start_date":"2025-10-07","primary_completion_date":"2027-06","completion_date":"2027-10","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":36,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995}],"countries":["United States"]},{"id":3688,"nct_id":"NCT06367738","title":"Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","sponsor":"University of California, Berkeley","registry_url":"https://clinicaltrials.gov/study/NCT06367738","tracker_url":"publication.php?id=3688","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-10","last_update_date":"2025-10-21","start_date":"2025-11","primary_completion_date":"2026-12-30","completion_date":"2027-12-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":40,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"SINGLE_GROUP","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Aging"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275}],"countries":["United States"]},{"id":3668,"nct_id":"NCT06899594","title":"A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine","sponsor":"Kevin Murnane","registry_url":"https://clinicaltrials.gov/study/NCT06899594","tracker_url":"publication.php?id=3668","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-10-07","start_date":"2025-04-04","primary_completion_date":"2027-03","completion_date":"2027-03","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":20,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Methamphetamine Use Disorder"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"80808de48757f3ab86bdc23356fb96e401f106b134925f19370a66e24bdd35b1","facility":"LSU Health Shreveport","city":"Shreveport","region":"Louisiana","country":"United States","lat":32.525149999999996,"lon":-93.75018}],"countries":["United States"]},{"id":3435,"nct_id":"NCT06368492","title":"The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.","sponsor":"Maastricht University","registry_url":"https://clinicaltrials.gov/study/NCT06368492","tracker_url":"publication.php?id=3435","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-09","last_update_date":"2025-09-15","start_date":"2024-05-03","primary_completion_date":"2025-12","completion_date":"2025-12","study_type":"INTERVENTIONAL","phases":["NA"],"enrollment":{"count":35,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Fibromyalgia"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Hypnosis script","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f26bee6a0a45781053d5dfa012f97c3db3997369bce9de3db4cd4cc54b57daa6","facility":"Maastricht University","city":"Maastricht","region":"Limburg","country":"Netherlands","lat":50.848329999999997,"lon":5.6888899999999998},{"key":"53531a82330e40fa414108ebaefe85390bc30ce9a2da6c9a7d1d8128d9c6c3a2","facility":"Leiden University Medical Center","city":"Leiden","region":"South Holland","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998}],"countries":["Netherlands"]},{"id":3708,"nct_id":"NCT06796361","title":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06796361","tracker_url":"publication.php?id=3708","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-05","last_update_date":"2025-05-28","start_date":"2025-04-21","primary_completion_date":"2026-08","completion_date":"2026-08","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":16,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"Ketanserin 40mg plus Psilocybin 40mg","type":"DRUG"},{"name":"40mg Psilocybin","type":"DRUG"},{"name":"20mg Psilocybin","type":"DRUG"},{"name":"10mg Psilocybin","type":"DRUG"},{"name":"5mg Psilocybin","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"substances":["psilocybin","psilocin"],"sites":[{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3694,"nct_id":"NCT06592833","title":"Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","registry_url":"https://clinicaltrials.gov/study/NCT06592833","tracker_url":"publication.php?id=3694","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-05","last_update_date":"2025-05-14","start_date":"2025-02-25","primary_completion_date":"2028-03-01","completion_date":"2028-03-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Major Depressive Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Pimavanserin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"e61b82022d59d1b6f216840fa8e11fe15a6e63ddf70a4fefdcdd7e0f971a1974","facility":"Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"countries":["United States"]},{"id":3635,"nct_id":"NCT06731335","title":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","sponsor":"Unity Health Toronto","registry_url":"https://clinicaltrials.gov/study/NCT06731335","tracker_url":"publication.php?id=3635","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-03-30","start_date":"2025-03-05","primary_completion_date":"2026-08","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":30,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Chronic Neuropathic Pain","Pain Management"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Active Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"de943dc53921b98b85839676ebd9bd35ab84bed7e937ec479cae02f2f56e5fd9","facility":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864}],"countries":["Canada"]},{"id":3586,"nct_id":"NCT06899334","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT06899334","tracker_url":"publication.php?id=3586","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-03","last_update_date":"2025-03-27","start_date":"2025-04-01","primary_completion_date":"2026-08-01","completion_date":"2026-08-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":24,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"BASIC_SCIENCE","masking":"TRIPLE"},"conditions":["Healthy"],"interventions":[{"name":"LSD","type":"DRUG"},{"name":"Psilocybin","type":"DRUG"},{"name":"DMT","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999}],"countries":["Switzerland"]},{"id":3627,"nct_id":"NCT03289949","title":"The Neurobiological Effect of 5-HT2AR Modulation","sponsor":"Gitte Moos Knudsen","registry_url":"https://clinicaltrials.gov/study/NCT03289949","tracker_url":"publication.php?id=3627","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-12","last_update_date":"2024-12-16","start_date":"2017-03-03","primary_completion_date":"2030-06-01","completion_date":"2030-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"NON_RANDOMIZED","intervention_model":"SEQUENTIAL","primary_purpose":"BASIC_SCIENCE","masking":"SINGLE"},"conditions":["Basic Science"],"interventions":[{"name":"Psilocybine","type":"DRUG"},{"name":"Ketanserin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"194d419533160aa241e58316c109a3778e280f27677956060dac8d0bfae574c6","facility":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001}],"countries":["Denmark"]},{"id":3528,"nct_id":"NCT06378229","title":"Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus","sponsor":"University Hospital, Ghent","registry_url":"https://clinicaltrials.gov/study/NCT06378229","tracker_url":"publication.php?id=3528","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-09","last_update_date":"2024-09-19","start_date":"2024-05-21","primary_completion_date":"2026-03","completion_date":"2026-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Treatment Resistant Depression"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"de5de4cd4a64693d58b4d482b491ab2adbd6db4602a86d03c76d0c7dfa1737de","facility":"Ghent University Hospital","city":"Ghent","region":"Oost-Vlaanderen","country":"Belgium","lat":51.049999999999997,"lon":3.7166700000000001}],"countries":["Belgium"]},{"id":3438,"nct_id":"NCT06160232","title":"Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms","sponsor":"Brugmann University Hospital","registry_url":"https://clinicaltrials.gov/study/NCT06160232","tracker_url":"publication.php?id=3438","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2024-08","last_update_date":"2024-08-07","start_date":"2024-02-15","primary_completion_date":"2025-12-15","completion_date":"2026-06-15","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":62,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Severe Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin (high dose)","type":"DRUG"},{"name":"Active placebo (low dose of psilocybin)","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"dafa3859e760931a703dbfafba7ca9060f6a965b188b8bd05bfcdce5b2f5f81d","facility":"Brugmann University Hospital","city":"Brussels","region":"","country":"Belgium","lat":50.850450000000002,"lon":4.3487799999999996}],"countries":["Belgium"]},{"id":3632,"nct_id":"NCT05995769","title":"Mechanisms Supporting Psilocybin-assisted Psychotherapy for Alcohol Use Disorder: A Randomized, Controlled Clinical Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT05995769","tracker_url":"publication.php?id=3632","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2023-08","last_update_date":"2024-05-07","start_date":"2024-03-20","primary_completion_date":"2027-10-01","completion_date":"2027-10-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":128,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Use Disorder","Alcoholism"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529}],"countries":["Canada"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2017":1,"2021":2,"2022":1,"2023":3,"2024":20,"2025":41,"2026":35},"statuses":{"Recruiting":103},"conditions":{"Depression":10,"PTSD":6,"Healthy":6,"Major Depressive Disorder":6,"Opioid Use Disorder":6,"Depression - Major Depressive Disorder":5,"Anxiety":5,"Treatment Resistant Depression":5,"Alcohol Use Disorder":4,"Psilocybin":3,"Advanced Cancer":3,"Demoralization":3,"PTSD Symptoms":2,"Anhedonia":2,"Psychedelic Effects in Healthy Volunteers":2,"Anorexia Nervosa":2,"Cancer":2,"Pain Management":2,"Chronic Pain":2,"Psychological Distress":2,"Post Traumatic Stress Disorder":2,"MDD":2,"Depressive Disorder":2,"Phase I":1,"Alzheimer's Disease":1,"PTSD - Post Traumatic Stress Disorder":1,"PTSD, Post Traumatic Stress Disorder":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Parkinson's Disease (PD)":1,"Chronic Pelvic Pain":1,"Treatment-resistant Depression (TRD)":1,"Healthy Volunteer":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Depression, Anxiety":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Depressive Symptoms":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Chronic Low-back Pain":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Treatment-Resistant Depression":1,"Major Depression":1,"Psychological Stress":1,"Bipolar II Disorder":1,"Depression, Bipolar":1,"Suicidality":1,"Generalized Anxiety Disorder (GAD)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Parkinson Disease":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Psychedelic Experiences":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Obsessive-Compulsive Disorder":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Migraine":1,"Perception Disorders":1,"Depressive Sympotoms":1,"Tobacco Use Disorder":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Major Depressive Disorder (MDD)":1,"Atypical Parkinson Disease":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Existential Distress":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"Substance Use Disorder (SUD)":1,"OCD":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Healthy Volunteers":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Aging":1,"Methamphetamine Use Disorder":1,"Fibromyalgia":1,"Chronic Neuropathic Pain":1,"Basic Science":1,"Severe Alcohol Use Disorder":1,"Alcoholism":1},"sites":[{"key":"989968603bde40ea62cec15821beab8b75357cd99d372a1c9c6f3bbeebc55d37","facility":"Brown University School of Public Health","city":"Providence","region":"Rhode Island","country":"United States","lat":41.823990000000002,"lon":-71.41283},{"key":"28a3d9c38002b595ae213eb3bb81b2024aaf1d5bdcc3b9fd3ac81fe627252323","facility":"National Institute of Aging, Clinical Research Unit","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"ddc0834a1890df449d67ca69d92e76e6f1b5160403493ab29dfc1c2e1aed69c6","facility":"FL","city":"Miami","region":"Florida","country":"United States","lat":25.774270000000001,"lon":-80.193659999999994},{"key":"4b235d9fa455f60193f31a0d89a5dee284e9661ca9046ed4a1e57536aca09d6f","facility":"FL","city":"Orlando","region":"Florida","country":"United States","lat":28.538340000000002,"lon":-81.379239999999996},{"key":"a3f3b33aa62b155795dadc7cd5bdf343b9f66b44bc44a2ad0d5ee5fa338c2557","facility":"IL","city":"Chicago","region":"Illinois","country":"United States","lat":41.850029999999997,"lon":-87.650049999999993},{"key":"dbbb51357e4d710396c355b1f980917dd53615a81be8d319622d67aba5bb4e0e","facility":"MN","city":"Eden Prairie","region":"Minnesota","country":"United States","lat":44.854689999999998,"lon":-93.470789999999994},{"key":"c3798f7e7cf15a4eef1a10f53d46184aaf3eec07c5a23828e9e7a968feadf7db","facility":"NE","city":"Lincoln","region":"Nebraska","country":"United States","lat":40.799999999999997,"lon":-96.666960000000003},{"key":"1d793527c906ffb5c84860c6577d23027344e23eb25b29e2b74f8a07d64f5514","facility":"NV","city":"Las Vegas","region":"Nevada","country":"United States","lat":36.174970000000002,"lon":-115.13722},{"key":"6214ddb8e0d6a9b9b5b4cd7c9be7f1b1f04d1f4f17ff5715a68f589a0d3c671a","facility":"NY","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"593189837e8532b432a369deaaa9a95dd6d9069e9ee0f7d4f302734d14cb430e","facility":"BC","city":"North Vancouver","region":"British Columbia","country":"Canada","lat":49.316360000000003,"lon":-123.06934},{"key":"9d7c1530695da1e0dbe5d0029c61521b74c434cedec820dcadef26feb9ead43e","facility":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"8d12e2a0185c4db904e4654a720cc76843665c984d8a6666af2af6398451abcf","facility":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"ce511e3de8dae05034afdb25043c5e28d581eecc32497eda1b36dd3837c67ae4","facility":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"c0770de3d29c4c5f32a2af8475f2c25f664dc150eb0612e3bad6f32b5afb5313","facility":"Oregon Health & Science University","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"20f0c712ea58b6615610fe11e7cff939bcc55adfffcd8761309ca251e8acfc7d","facility":"GHU Paris Psychiatrie and Neurosciences","city":"Paris","region":"","country":"France","lat":48.853409999999997,"lon":2.3488000000000002},{"key":"43d57f1d479805418491a2b4e825f4a61463da217d6483cb15a9c517f345d284","facility":"University of California San Francisco (UCSF) Department of Neurology","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"0473ab642c74b3812c946daf78fe3c51c20132227d55cd3b18f186955bf391f2","facility":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"2392816208ad8a6692839d858f70a09054f7ea063608cc805707f539d666e13b","facility":"Emory University Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","lat":33.749000000000002,"lon":-84.387979999999999},{"key":"6f007287e1a63fa09fd71b03e4e4b72f285c5af84c8385a3eed252bc9a13b363","facility":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","lat":42.358429999999998,"lon":-71.05977},{"key":"22268aacd3575a268c889e749c8576127c9bff8a9e8343b4058a94d77d976383","facility":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","lat":41.256259999999997,"lon":-95.940430000000006},{"key":"bf586d38e3cc5e261d1c6e575c24ec47a2175ffd3a3a156c666afe314b54f80c","facility":"New York University Langone Health, Center for Psychedelic Medicine","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"fdeccc6664a6555feb9443c7f9547c8dc94264e878e864489fd4b43c0a16451a","facility":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"b080767d21c0ebe8aea0aba1c3f1a88355bed0e01997cb41cb5704abd0b086dc","facility":"Djavad Mowafaghian Centre for Brain Health","city":"Vancouver","region":"British Columbia","country":"Canada","lat":49.249659999999999,"lon":-123.11933999999999},{"key":"aa8f99cb753e6ee68d3c63b2cdb1b7e7d90b1680cb84bc239d625d80bd4e6c8b","facility":"Department of Psychiatry, University of Ottawa, The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ab54d44984a52b7a2aba12f9808b881d3f2fa4a702669885a0a10983ba498e39","facility":"Department of Psychiatry, University of Toronto, University Health Network,","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"5694dcf845a6c481e3dda16b85afa7a73d3936087eefe461fcc9694177d080de","facility":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"3a46b1d6e7fd8e6d4ac3522c52ea258b11d52f64ed81a85f442fdb36db5182f6","facility":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"43d6a4c1bec6b0da7fbcdcf29f22e29eb9ee146f88b69aa1d4bc718a46bed666","facility":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"52bc2180526f10b62a5aca748b84f9b3b723aee40e4b7ba311fbe63f85e74ca8","facility":"University of California San Francisco, Sandler Neuroscience Building","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"b1b7385307b2710c76b5175c36619a7edcaff39e015a0a2e8cb2e1b125a2f6bb","facility":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"9d73c96f237ac68fbda3d911e4b1f4df70d78bffe439fcbd3af6fdd7e0b5b445","facility":"Outpatient CTRC","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"26536ff41048bd47e18a2ae19bf7955b33e3305e2417d2a442cc3e762d6f37db","facility":"University of Colorado Cancer Center","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"2e7548466e831b567e38ef1e8fdd7baae3817e9b4e2a89bc35dca43d64edbecb","facility":"UC San Diego","city":"San Diego","region":"California","country":"United States","lat":32.715710000000001,"lon":-117.16472},{"key":"61ce79cfaa08fedbb10711df8d7c73a357fd5df0b146e4b4ff109a1f1ba7fd39","facility":"Toronto Western Hospital (University Health Network)","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"bf2adfb756d244974a952f7c5c58e6f72f66cbbd5ba63e61a8b987fa1820f128","facility":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"277ec95effb37a499f97d6fb82da461e2d3790bb840eb8be0d307666a1a93593","facility":"Psykiatrikliniken, Baravägen 1","city":"Lund","region":"","country":"Sweden","lat":55.705840000000002,"lon":13.193210000000001},{"key":"1094674cfb576eb3aba9c610abfa1ec8007d88c3fc30323de895b78b257dc9ca","facility":"Birmingham VA Medical Center, Birmingham, AL","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"36ded30328be4e5de016f706a8efcb9e2ce3181d513bae1f031f8c88931e15dd","facility":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","lat":33.20984,"lon":-87.56917},{"key":"673eee709be8746b7b99358264e9a830cab9eff575766127a823456961139800","facility":"VA Portland Health Care System, Portland, OR","city":"Portland","region":"Oregon","country":"United States","lat":45.523449999999997,"lon":-122.67621},{"key":"5bc04aa77be1370761183e8a64f2c2e1129ef67efc98b5f6610da73065ccb37c","facility":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"cf2d4c3f9eed8457b9a5ca21d741ba54a1b036d130efd17e977384b0d89a5133","facility":"VA Puget Sound Health Care System Seattle Division, Seattle, WA","city":"Seattle","region":"Washington","country":"United States","lat":47.606209999999997,"lon":-122.33207},{"key":"72b096fd9021c9bfd550d9d949b2594137c212c14110e7c00e66d39b5f8101eb","facility":"UW School of Medicine and Public Health","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"41d7ef563025697eae67dcbab6ec20d0cf94934cb7a21f3999e9b581e150f205","facility":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"ae85e9f90db4bd1845b2a9817e008d4a625ffc046123c8a22344695349c7e230","facility":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","lat":42.377870000000001,"lon":-71.061999999999998},{"key":"cc8da94c896719bab57ed8dd47266c0ce0664ad555799300d442f1fe89aa2942","facility":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"da2bda06c1b463bdcf59130477fd36b92915811ee4ac0f0c25eafb7329fb0cb9","facility":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"5e54e3832bb9c4f6cddd3eeefc9951bb04903d8e26aedf819b29aa11a2e0c418","facility":"Kingston General Health Research Institute","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"e6baef990fbeb7d39fe3ae6170b4504d185d11acfac4b251c03198f2bd0ccd03","facility":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","lat":39.64499,"lon":-106.5942},{"key":"1b2819d4a8ca62168bb131d84bf5a2039f0800c02db6394dd76a4e6af80edf2c","facility":"James J. Peters Department of Veterans Affairs Medical Center","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"7f09a842484186a75c6232177464293472d56c43d4d49f24f37efcb6c9cbbbb8","facility":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"fe41ad3987d6de6fe68c69a1ba7b8083c49c8f7f3ed503bb29759b163851e03c","facility":"Univeristy of Southern California Brain and Creativity Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"1dd82fd9cc6558717200ae66d13a24d08c805492d49f67b2d8f9edc800d2c261","facility":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"a9c873ac063d6e120c29fe3a990563df65d56f36d533e4becc50b462afacd39c","facility":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","region":"","country":"Israel","lat":32.080880000000001,"lon":34.780569999999997},{"key":"150ee05b89013f57afa3d4437262fc96492708dbef022aa3d4706d1b2f9b8bcd","facility":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"56dbd951047579f5e7cb6365abb06b654904e94f48585c22b28b8f01d8930412","facility":"Centro de Pesquisas Matteo Ricci","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","lat":-22.906420000000001,"lon":-43.182229999999997},{"key":"b7ce275dcf24ed96a64d133fef7a20f86f0b05456f00dfb40319b4e098140d69","facility":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","lat":32.221739999999997,"lon":-110.92648},{"key":"53cdbf22033ee2308c3b87787fc126f7b960b463f408d5adce7f8bc3876c2e09","facility":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"e80ae31010614821a2c0251a43cb105eb5afdf4210df2d02fbca62249b4812cb","facility":"Institute of Health Science, Khyber Medical University","city":"Islamabad","region":"Capital","country":"Pakistan","lat":33.72148,"lon":73.043289999999999},{"key":"482052fef0467a4bb441cf6e5d88301072e19c45a3a032776b1d48bce47e7a68","facility":"Hayatabad Medical Complex Peshawar","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"54a0606875858be17f5c6f12f6ec10397681ed8e3c5b816b0964b25c06587ac1","facility":"Khyber Medical University","city":"Peshawar","region":"KPK","country":"Pakistan","lat":34.008000000000003,"lon":71.578490000000002},{"key":"ef06e3a474fd2949d20a68ee09bed05400191915922ddddc3e80085918c45336","facility":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","lat":41.270650000000003,"lon":-72.947050000000004},{"key":"104bc03ef1be3eb283fc88bf5fce3e5ff6c85007bff327791c7a04846f88d35a","facility":"William Osler Health System","city":"Brampton","region":"Ontario","country":"Canada","lat":43.683410000000002,"lon":-79.766329999999996},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"6f7cb2e1921867a894d4f688041519f8adcacf7b68acf4348e2e37c6661d4cdf","facility":"St. Joseph's Healthcare","city":"London","region":"Ontario","country":"Canada","lat":42.98339,"lon":-81.233040000000003},{"key":"f934fa0d3d51d6c774793a28fc64efcf90b8e28198269a1250a0c3f99f3ed6f9","facility":"South Lake Regional Health Centre","city":"Newmarket","region":"Ontario","country":"Canada","lat":44.050109999999997,"lon":-79.466309999999993},{"key":"25666f03708722f78f57cf2a417d211304fca135b845052bac716c024043384f","facility":"Bruyere Health","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"191b97d23002f5fc0aef25ec189e10d4d9cfe3306186fed0ac8629e958a94280","facility":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","lat":45.411169999999998,"lon":-75.698120000000003},{"key":"ef9bc15ff41fe07277a1de400fafab1b05a763305b6e78adf15926ff3f12ea42","facility":"McGill University Health Centre","city":"Montreal","region":"Quebec","country":"Canada","lat":45.508839999999999,"lon":-73.587810000000005},{"key":"f03299e8c6bc2c4a865cc090ea047d3a962eb50dc47bdd65bf9ed339007f853b","facility":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","lat":37.871589999999998,"lon":-122.27275},{"key":"6432b7631d0ccc20e148c4eddca2643abaa034857cab41344671f3fb747879b1","facility":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","lat":39.952379999999998,"lon":-75.163619999999995},{"key":"0fef037c24d643378aa9f37a26412f8308ddc2ac490d10c8ef10ee242ac4bfb8","facility":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","lat":43.073050000000002,"lon":-89.401229999999998},{"key":"323f6a0d326702feb35e14a7b9184860791df3488ef3495f35a0de3236897eb0","facility":"Centre Hospitalier de la Côte Basque","city":"Bayonne","region":"","country":"France","lat":43.493160000000003,"lon":-1.4730000000000001},{"key":"5ffc1075f6bec0dadbe8bc3e065b0e1b877e363dbf6627b545bf4beffff70757","facility":"CHU Besançon","city":"Besançon","region":"","country":"France","lat":47.248779999999996,"lon":6.0181500000000003},{"key":"a6fd2e2e6ed56330ba623e90ee634f2d4915008c80b207dde3ed9faf47960e8d","facility":"CHU de Bordeaux","city":"Bordeaux","region":"","country":"France","lat":44.841239999999999,"lon":-0.58045999999999998},{"key":"14ea4a2b72ea454ee54e0e0774dcd9904223f73df3e3c531e7d5f0cfa141d839","facility":"CHU Brest","city":"Brest","region":"","country":"France","lat":48.39029,"lon":-4.4862799999999998},{"key":"f89e51a603fb7d3311c5aa5e1f5fa8b931a29eab96f579366c7020edef6d63eb","facility":"CH Le Vinatier","city":"Bron","region":"","country":"France","lat":45.73865,"lon":4.91303},{"key":"979bc0acd73468b3e9e5e478d1eb8b6146cdb655e43714015ace7d5e264ec03f","facility":"CHU de Nantes","city":"Nantes","region":"","country":"France","lat":47.21725,"lon":-1.5533600000000001},{"key":"4a89439659e3f06e4c831d2ab54c7949dfe24a09c19f411896d75ff90f0f0fde","facility":"CHU de Nîmes","city":"Nîmes","region":"","country":"France","lat":43.836649999999999,"lon":4.3578799999999998},{"key":"3f02e2b16edbfc081f5b9dfd08b8a203c4b47bf73ba2fa3f66915ff73cb56a9b","facility":"CHU Saint-Etienne","city":"Saint-Priest","region":"","country":"France","lat":45.696510000000004,"lon":4.9438500000000003},{"key":"8bf6e838a381bd54a71fab76ec32329ee9e85502264bce18bfd4dce5416f5ef3","facility":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"bc86403d1c9f2442271abec1230ce766e06c064f627db179acfcfde14e4f85e3","facility":"New York University","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"dab33405eff5190f72da59b78efc1f976cb32567ca0ed993e0fa62358b51185e","facility":"The Ohio State University Medical Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"c2b8ac7cbe1dfe7dfd4a496dfe7196accedd01cd287918d4f9a3f24cacfa9649","facility":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"7d95aada95625af597e7f99db1d1499ad1edcc4815ba129bc332e93fab4f316e","facility":"University of Virginia","city":"Charlottesville","region":"Virginia","country":"United States","lat":38.029310000000002,"lon":-78.476680000000002},{"key":"198d5bb2b7293acb85f77709d851433288e2bd94aaa3b81634c72028f5024289","facility":"UCSF Mission Bay","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"1a9055771782109a22253dda7644c3735bc7758f34ad52e7af1cb4208b995f4b","facility":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"d57ba16f21b5e5513a5f85825fdee40ef908d80b41bdf65f0b98dc075445577b","facility":"Ohio State University Comprehensive Cancer Center","city":"Columbus","region":"Ohio","country":"United States","lat":39.961179999999999,"lon":-82.99879},{"key":"815dca1c51560a2771c70b436758dad26e0e7113577a98422d68f884f890d354","facility":"National Institute of Mental Health","city":"Prague","region":"","country":"Czechia","lat":50.088039999999999,"lon":14.42076},{"key":"34a79f541cea47ad7b374bfde6da99960b2120ed088ec92eaa3df41e96eb7390","facility":"Bispebjerg Hospital","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"27d7b4df35cb1e0b4d4349418e100597b52afe044578477ac7a1e36059b373ba","facility":"University Medical Center Groningen","city":"Groningen","region":"Provincie Groningen","country":"Netherlands","lat":53.219169999999998,"lon":6.5666700000000002},{"key":"0aaa8840c6965661f46de84dc613d0842e14dbd41f5597c5ec01c47dcbaabd26","facility":"Champalimaud Foundation","city":"Lisbon","region":"","country":"Portugal","lat":38.725090000000002,"lon":-9.1498000000000008},{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"5f5211b90f32857d4a2b3783ed0a8d299123b97980aecac0dc9fd0a8439396d7","facility":"region Västra Götaland","city":"Gothenburg","region":"Göteborg","country":"Sweden","lat":57.707160000000002,"lon":11.96679},{"key":"56f6973050dae2540f6877689b3512d938f70ee52e4bd51ebc6542c3a6adaa89","facility":"Norra Stockholms Psykiatri","city":"Stockholm","region":"Stockholm County","country":"Sweden","lat":59.32938,"lon":18.068709999999999},{"key":"384faadacad1af176bc642c675eb5c7bdc2ad01c26ea770b0702143798b59dfa","facility":"Psykiatriska Kliniken, Akademiska Sjukhuset","city":"Uppsala","region":"Uppsala County","country":"Sweden","lat":59.858820000000001,"lon":17.63889},{"key":"046953804b0a225af99cd7bd152e5969b25e38978f43961e75862c8ef2f53fc5","facility":"Örebro sjukhus","city":"Örebro","region":"Örebro County","country":"Sweden","lat":59.274120000000003,"lon":15.2066},{"key":"d8875f7f4d4e3f36b2235d0201354748ba8de08e94380e3b3cb5c9f3cfca0d9e","facility":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"0baab4fede4fc6054da41261b4cd831dfa37af046f4a5adc5c2912ab388dff0e","facility":"Federal University of Latin American Integration","city":"Foz do Iguaçu","region":"Paraná","country":"Brazil","lat":-25.547779999999999,"lon":-54.588059999999999},{"key":"e1f0adb91f843c24eebaa1127eb64810250131187c9a0be296d3c4b271f3acb7","facility":"Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry","city":"Vienna","region":"State of Vienna","country":"Austria","lat":48.208489999999998,"lon":16.37208},{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"57b51432bd54eead1665bf308d75c58452112099cecfea39a38a9a4ae8d6e95d","facility":"UAB Beacon Tower","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"53cb5faca3c60ecf068797736403edeb0302d95d0a85337b9536bbc345ef7916","facility":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","lat":41.308149999999998,"lon":-72.928160000000005},{"key":"60b561826ea1087d0a6075e09763aebb8728c09f0183a3d029f1558c69e69bd3","facility":"Mind Medicine Australia Clinic","city":"Abbotsford","region":"Victoria","country":"Australia","lat":-37.799999999999997,"lon":145},{"key":"bc24127b43b0f70565a09f33f689e5c1c9ef6f31ba136c7650ba0fd99b8289cb","facility":"Paratus Clinical Research Melbourne","city":"Northcote","region":"Victoria","country":"Australia","lat":-37.766669999999998,"lon":145},{"key":"adfbd3436ba3de0148122053ef79072e74006b058256ba9b8f2d0a035013fd6b","facility":"Empax Centre","city":"Leederville","region":"Western Australia","country":"Australia","lat":-31.93628,"lon":115.8419},{"key":"10c44137a9b4880068299ddcb07a1eb31ce3cb82a82abd191c04b907f1430cba","facility":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","lat":39.290379999999999,"lon":-76.612189999999998},{"key":"d6737ae6c1d4e88b0250366ac1706c0eb50510292a7547d4474ad9750824e06e","facility":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"429fe69d07db5cabcda31c9415fb3b7bade24763ccdfea22c895d8c381fdd472","facility":"Hadassah Medical Organization, Jerusalem, Israel","city":"Jerusalem","region":"","country":"Israel","lat":31.76904,"lon":35.216329999999999},{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"e9371a41662463aee2a73b489b08fd54498561d5f98b540ab6947525b5b46514","facility":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","lat":29.763280000000002,"lon":-95.36327},{"key":"bd9ef7ba5708708e271ac4223cd8f759659fe972f273d761152a6c0134e8622e","facility":"Imperial College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"ea083ab2fc2ae83a35a58fe8386ef0b69ef14561d64fefb0069b5be4bb994b97","facility":"University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","lat":49.883069999999996,"lon":-119.48568},{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"96f2bd88eed1d3818ed1f1051b3996f8f528fdb49be756ea1e8244ba9e93f7ba","facility":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","lat":41.66113,"lon":-91.530169999999998},{"key":"6ca657d87e4528cc481a8c1baf8515a664bf591f795d28d79266623762f21568","facility":"University College London","city":"London","region":"","country":"United Kingdom","lat":51.50853,"lon":-0.12573999999999999},{"key":"15784c018ae70fcfb16f6b7f984cc9132fb865e356d99c82ce788fa1bede4b39","facility":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","lat":30.267150000000001,"lon":-97.74306},{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001},{"key":"f6e857b260b7429beba395444fac2f816d9d86eb9ae717988e7a361b734fead7","facility":"Mental Health Center Beer Sheva","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913},{"key":"5b227dd2e6263d32525d87b3fb390db797275e595c1806af406b57648ac86736","facility":"Beer Sheva Mental Health Center","city":"Beersheba","region":"","country":"Israel","lat":31.251809999999999,"lon":34.7913},{"key":"80808de48757f3ab86bdc23356fb96e401f106b134925f19370a66e24bdd35b1","facility":"LSU Health Shreveport","city":"Shreveport","region":"Louisiana","country":"United States","lat":32.525149999999996,"lon":-93.75018},{"key":"f26bee6a0a45781053d5dfa012f97c3db3997369bce9de3db4cd4cc54b57daa6","facility":"Maastricht University","city":"Maastricht","region":"Limburg","country":"Netherlands","lat":50.848329999999997,"lon":5.6888899999999998},{"key":"53531a82330e40fa414108ebaefe85390bc30ce9a2da6c9a7d1d8128d9c6c3a2","facility":"Leiden University Medical Center","city":"Leiden","region":"South Holland","country":"Netherlands","lat":52.158329999999999,"lon":4.4930599999999998},{"key":"ebda5e93566d65c5a0d08874906c8e63c9d620a77b25a4867b0465a3d920d8ef","facility":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"e61b82022d59d1b6f216840fa8e11fe15a6e63ddf70a4fefdcdd7e0f971a1974","facility":"Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"de943dc53921b98b85839676ebd9bd35ab84bed7e937ec479cae02f2f56e5fd9","facility":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","lat":43.706429999999997,"lon":-79.39864},{"key":"ac63a9b87b0d17c174df6cd33e9b23cdf05c23cc85c8cd317f6c08206a61f3ac","facility":"University Hospital","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"194d419533160aa241e58316c109a3778e280f27677956060dac8d0bfae574c6","facility":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","region":"","country":"Denmark","lat":55.675939999999997,"lon":12.565530000000001},{"key":"de5de4cd4a64693d58b4d482b491ab2adbd6db4602a86d03c76d0c7dfa1737de","facility":"Ghent University Hospital","city":"Ghent","region":"Oost-Vlaanderen","country":"Belgium","lat":51.049999999999997,"lon":3.7166700000000001},{"key":"dafa3859e760931a703dbfafba7ca9060f6a965b188b8bd05bfcdce5b2f5f81d","facility":"Brugmann University Hospital","city":"Brussels","region":"","country":"Belgium","lat":50.850450000000002,"lon":4.3487799999999996}],"enrollment":{"sum":6703,"known_trials":103},"registry_checked_at_utc":"2026-10-09 01:24:43"}